News archive
Showing 663 results
November 2019
-
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications(1)Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63… -
Media Release
New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
- PsO at Work provides a critical resource to help the more than 8 million Americans with psoriasis balance the demands of their jobs with managing their symptoms(1)- Lauper will highlight her PsO at… -
Media Release
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
October 2019
-
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
- STEP Program is available to US-based nonprofit patient advocacy organizations- Recipients will receive funding to support proposals that demonstrate innovation in awareness and education, self-… -
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of… -
Media Release
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
-
Media Release
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
-
Media Release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)- Novartis plans FDA submission… -
Media Release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
September 2019
-
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate… -
Media Release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1